Alamar Biosciences

About Alamar Biosciences

Alamar Biosciences is a proteomics company focused on empowering researchers to interrogate the human proteome with unprecedented breadth, depth, and high-throughput precision. Their mission is to enable the earliest detection of disease by advancing precision proteomics, providing cutting-edge solutions for biomarker discovery and validation to academic institutions, core labs, and biopharmaceutical companies.

Products & Services

ARGO HT System:A fully automated, high-throughput proteomics platform for precise protein detection at the push of a button.

NULISA Platform:A technology offering unparalleled sensitivity and dynamic range for detecting protein biomarkers from fluid samples.

NULISA Assays for Immunology:Assays designed to profile protein biomarkers related to immunological research.

NULISAseq CNS Disease Panel 120:A panel for detecting brain-derived pTau isoforms in plasma, aiding neurodegenerative disease research.

NULISA Inflammation Panel:A panel for profiling inflammation-related protein biomarkers.

NULISAqpcr Custom Assay Development:Custom assay development services for specific protein detection needs.

Alamar Analysis Solutions:Analytical solutions to support proteomics research and data interpretation.

Technology Access Program:A program providing access to Alamar's cutting-edge proteomics technologies.

Specialties

Precision Proteomics Protein Biomarker Analysis Fluid Biomarker Detection High-Throughput Proteomics Ultra-Sensitive Protein Detection Neurodegenerative Disease Research Immunology Research Oncology Research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Convertible Notes T: - FT: Convertible Notes	A: 50000000 MR: - FA: more than $50 million FAN: 50000000	D: 2026-01-11 FD: 2026-01-11	4 investors
2	RT: Investment T: - FT: Investment	A: 10000000 MR: - FA: $10M FAN: 10000000	D: 2025-01-08 FD: 2025-01-08	1 investors
3	RT: Series C T: - FT: Series C	A: 128000000 MR: - FA: $128 Million FAN: 128000000	D: 2024-02-26 FD: 2024-02-26	1 investors

Convertible Notes Latest

2026-01-11

$50.0M

4 investors (Pro only)

Investment 2025-01-08

$10.0M

Series C 2024-02-26

$128.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

Y

Yuling Luo

Founder, Chairman & CEO

T

Tod White

CFO/CBO

S

Steve Chen

Founder, COO

X

Xiao-Jun Ma

CTO

Y

Yiyuan Yin

Founder, VP of Technology

A

Anna Berdine

SVP, Marketing

View 6 more team members with Pro

Unlock Full Team Directory

Recent News